WVP
ARDS

Worth Venture Partners’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Worth Venture Partners’s Portfolio ARDS Stock Details ARDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-105,413
Closed -$780K – 143
2021
Q2 		$780K Hold
105,413
– – 0.29% 75
2021
Q1 		$622K Buy
105,413
+17,481
+20% +$118K 0.3% 75
2020
Q4 		$534K Buy
+87,932
New +$614K 0.42% 59

Other funds holding ARDS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MWM
Minot Wealth Management Westwood, Massachusetts $389M AUM 3.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Worth Venture Partners's ARDS Position: Q3 2021 in Review

Worth Venture Partners sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2021, closing a stake of 105,413 shares — an estimated $780K sold.

Worth Venture Partners first reported a position in ARDS in Q4 2020 and held it in 3 quarters. The position peaked at $780K in Q2 2021. 18 funds tracked by Wall St. Rank hold ARDS as of Q3 2021.

  • Worth Venture Partners reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Worth Venture Partners sold 105,413 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2021, an estimated $780K.
  • Worth Venture Partners first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Worth Venture Partners's Aridis Pharmaceuticals Inc. Common Stock position peaked at $780K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2021.

Based on Worth Venture Partners's 13F filing for Q3 2021, filed 15 Nov 2021.